BIOCHEMISTRY OF THE BOMBESIN-LIKE-PEPTIDE RECEPTOR

肺癌是美国癌症死亡的主要原因。 大约25%的病例是小细胞肺癌(SCLC)， 尽管进行了积极和有毒的治疗，但携带不到10% 存活时间为五年。这个项目的最终目标是 开发小细胞肺癌的新治疗策略。小细胞肺癌细胞分泌 并含有一种生长因子，蛙皮素，它能刺激他们的 通过与特定的细胞表面受体相互作用而生长。 这种相互作用的中断应该会导致细胞死亡。这 项目建议1)表征和提纯 这种生长因子的受体，蛙皮素；2)描绘 信号转导的生物化学机制导致 细胞增殖；3)利用定义的属性 蛙皮素与其受体的相互作用及其纯化 受体本身，开发新的诊断和治疗 应用单抗治疗小细胞肺癌的方法探讨 抗体、毒素结合物和配体类似物。

Lung cancer is the leading cause of cancar deaths in the U.S. About 25% of cases are small cell lung carcinoma (SCLC), which, despite aggressive and toxic therapy, carries a less than 10% survival at five years. The ultimate goal of this project is to develop new therapeutic strategies for SCLC. SCLC cells secrete and contain a growth factor, bombesin, which stimulates their growth by interaction with a specific cell surface receptor. Disruption of this interaction should lead to cell death. This project proposes 1) to characterize the properties of and purify the receptor for this growth factor, bombesin; 2) to delineate the mechanism of signal transduction biochemically which results in cell proliferation; 3) to utilize the defined properties of the interaction between bombesin and its receptor, and the purified receptor itself, to develop new diagnostic and therapeutic approaches to the management of SCLC using monoclonal antibodies, toxin conjugates and ligand analogs.